ASND•benzinga•
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Summary
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 13, 2025 by benzinga